MIXED DOSAGE FORM OF CMF (CYCLOPHOSPHAN-METHOTREXATE-5-FLUOROURACIL), METHOD FOR PREPARING MIXED DOSAGE FORM OF CMF (CYCLOPHOSPHAN-METHOTREXATE-5-FLUOROURACIL) (VERSIONS) AND METHOD FOR LYMPHOTROPIC INTERSTITIAL ADMINISTRATION OF MIXED DOSAGE FORM OF CMF (CYCLOPHOSPHAN-METHOTREXATE-5-FLUOROURACIL) FOR TREATING TUMOURS Russian patent published in 2013 - IPC A61K31/675 A61K31/513 A61K31/519 A61K31/198 A61K9/08 A61J3/00 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to clinical lymphology, pharmacology and oncology. A mixed dosage form of CMF (cyclophosphan-methotrexate-5-fluorouracil) for lymphotropic interstitial administration in chemotherapy contains cyclophosphan, methotrexate, 5-fluorouracil, normal saline NaCl, and if necessary, novocaine, in weight ratio to provide pH of the mixture equal to physiological pH of the interstitial tissue within the range of 6.9 to 7.2. There are also described 2 versions of the method for preparing the mixed dosage form of CMF. Treating the tumours involves lymphotropic interstitial administration of the mixed dosage form of CMF in the amount of 3 to 10 units either in the lymphatic region of the tumour, or peritumourally (next to the tumour) two-three times a day, 8 to 12 injections a month.

EFFECT: mixed dosage form of CMF according to the invention enables the long-term lymphotropic interstitial administration in treating solid tumours.

4 cl, 3 ex